Dr. Reddy’s reports success for Russian Covid-19 vaccine Sputnik V
Indian pharma company Dr. Reddy’s Laboratories announced that Sputnik V, a registered Covid-19 vaccine in Russia, has succeeded in a phase 2 trial in India by meeting the primary endpoint of safety. An independent data and safety monitoring board (DSMB) has recommended the Sputnik V Covid-19 vaccine to be advanced to a phase 3 trial […]
Novavax has initiated its first phase 3 clinical trial to assess the efficacy, safety, and immunogenicity of its NVX-CoV2373 COVID-19 vaccine candidate. The US vaccine development company is carrying out the late-stage trial in the UK in partnership with the UK government’s Vaccines Taskforce. The phase 3 trial of NVX-CoV2373 will aim to enroll and […]
Continue reading …
ENSEMBLE Covid-19 vaccine trial : Johnson & Johnson (J&J) has launched a multi-nation phase 3 trial called ENSEMBLE for its JNJ-78436735 Covid-19 vaccine candidate (Ad26.COV2.S), which is being developed by its subsidiary – Janssen Pharmaceutical Companies. The US healthcare giant said that the ENSEMBLE vaccine trial has been initiated following positive interim results from its […]
Continue reading …Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan
August 8, 2020 No Comment
US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former’s COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is said to be a stable, prefusion protein produced by using the recombinant protein nanoparticle technology of Novavax. The coronavirus vaccine candidate also contains the company’s Matrix‑M adjuvant. Takeda […]
Continue reading …
Pharma majors Sanofi and GlaxoSmithKline (GSK) have reached an agreement with the UK government for supplying up to 60 million doses of their jointly developed COVID-19 vaccine candidate. The agreement will be subject to a final contract issued by the British government. The COVID-19 vaccine candidate has been developed by Sanofi in partnership with British […]
Continue reading …COV001 clinical trial results : Oxford vaccine ChAdOx1 nCoV-19 triggers strong immune response
July 20, 2020 No Comment
COV001 clinical trial results : AstraZeneca and Oxford University said that interim results from the phase 1/2 COV001 clinical trial showed the ChAdOx1 nCoV-19 vaccine (AZD1222) to be well tolerated besides generating strong responses in all evaluated participants against the COVID-19 causing SARS-CoV-2 virus. The early-stage COVID-19 vaccine trial is being led by Oxford University, […]
Continue reading …G42 Healthcare begins phase 3 trial of Sinopharm COVID-19 inactivated vaccine candidate in UAE
July 20, 2020 No Comment
Sinopharm COVID-19 inactivated vaccine candidate : Chinese vaccine manufacturer Sinopharm CNBG has launched a phase 3 trial of its COVID-19 inactivated vaccine candidate, in collaboration with G42 Healthcare, in the UAE. The vaccine developer had found success with the phase 1 and phase 2 clinical trials of the coronavirus vaccine candidate in China. Its vaccine […]
Continue reading …
Pfizer and BioNTech said that BNT162b1 and BNT162b2, two vaccine candidates developed to give protection against the SARS-CoV-2 virus have been given the fast track designation from the USFood and Drug Administration (FDA). The two vaccine candidates are part of the four investigational vaccine candidates that are being jointly developed by the companies under their […]
Continue reading …
Imperial College London said that it has dosed the first healthy volunteer with its COVAC1 coronavirus vaccine candidate, which has been developed using the new self-amplifying RNA (saRNA) technology. The university claimed that the COVID-19 vaccine candidate has gone through rigorous pre-clinical safety tests, and in animal studies, it has been demonstrated to be safe, […]
Continue reading …
US-based Catalent said that its subsidiary Catalent Biologics has bagged a contract to provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Anagni, Italy, and prepare for large-scale commercial supply of AZD1222, the adenovirus vector based COVID-19 vaccine candidate of the University of Oxford. Catalent said that the agreement fast tracks […]
Continue reading …
Business News Today
- Dr. Reddy’s reports success for Russian Covid-19 vaccine Sputnik V
- TCS rolls out Autoscape solution suite for autonomous and connected vehicle experiences
- Infosys Q3 2020 results : Indian IT services giant reports $705m net profit
- Safehold Special Risk acquires motorsports insurance firm WSIB Insurance
- OncoSec Medical begins phase 2 OMS-104 melanoma trial with TAVO, OPDIVO combo
- Thoma Bravo-backed Majesco acquires insurtech company ClaimVantage
- Tata Power gets LOA from KSEBL for 110MW solar power project in Kerala
- Albemarle to invest up to $50m to double lithium production at Silver Peak facility
- Westland Insurance acquires Nova Scotia-based Storm Insurance Group
- Indian B2B ecommerce platform udaan bags $280m in new funding round
